drugset / Trial / NCT05875441

Efficacy and Safety Study of Moxidectin in Adults With Scabies

NCT05875441

Phase 2 Completed 200 enrolled Medicines Development for Global Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.

Timeline

Start
2023-11-23
Primary completion
2024-11-27
Completion
2025-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxidectin Other / unclassified 8 mg
Subject Moxidectin Other / unclassified 16 mg
Subject Moxidectin Other / unclassified 32 mg

Indications